Markets · 1 sources covering this

Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff

Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

MarketWatchCenter·37m ago
Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff
Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.
Read at MarketWatch →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/13e3d2056df6113eedbff74b036ddf3130415513"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Novartis&#x2019;s failed trial for cholesterol drug leads to broad biopharma stock selloff"></iframe>

Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff

How 1 sources are covering this

Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff

More from Markets

Oracle’s stock gets a boost as the OpenAI ecosystem comes back into favor

Odd Lots: Why Money Launderers Love $100 Bills

US Targets Iran’s Airlines as New Sanctions Push Continues

Private Credit’s Tokenization Revolution

Reader

Trust & legal

Across the network

How 1 sources are covering this

Novartis&#x2019;s failed trial for cholesterol drug leads to broad biopharma stock selloff

More from Markets

Oracle&#x2019;s stock gets a boost as the OpenAI ecosystem comes back into favor

Odd Lots: Why Money Launderers Love $100 Bills

US Targets Iran’s Airlines as New Sanctions Push Continues

Private Credit’s Tokenization Revolution

Reader

Trust & legal

Across the network

Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff

Oracle’s stock gets a boost as the OpenAI ecosystem comes back into favor